IMEP is a chemotherapy regimen that is effective for nasal NK- / T-cell lymphoma. This chemotherapy regimen was also tested in Hodgkin disease as a part of a multidrug alternating scheme COPP / ABV / IMEP. But in that setting it showed no advantage in efficacy and toxicity compared to the use of ABVD or the alternating COPP / ABVD scheme.
Drug regimen
| Drug | Dose | Mode | Days |
|---|---|---|---|
| (I)fosfamide | 1500 mg/m with mesna | IV infusion | Days 1-3 |
| (M)ethotrexate | 30 mg/m | IV bolus | Days 3 and 10 |
| (E)toposide | 100 mg/m | IV infusion | Days 1-3 |
| (P)rednisone | 120 mg | PO qd | Days 1-5 |
References
- "IMEP protocol in nasal NK/T-cell lymphoma". Archived from the original on 2014-09-11. Retrieved 2014-09-11.
- Treatment of advanced Hodgkin’s disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin’s Lymphoma Study Group HD6 trial